The information provided by bd represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bd.The following were reviewed as part of this investigation: patient severity, complaint and lot history review, applicable previous investigation(s), sample (if available), and applicable fmea documents.Based on a review of this information, the following was concluded: the complaint of unable to activate the safety mechanism is confirmed to be supplier related.One 22 ga x 0.75 in safestep infusion set was returned for investigation.Use residue was observed on the sample.The safety mechanism had not been engaged.An attempt to activate the safety mechanism revealed resistance.Additional force was required.Microscopic observation of the needle base and metal over sleeve revealed residual material that appeared to be adhesive used in the manufacturing process.The material was observed to fluoresce under uv lighting.Based on the condition of the returned sample, the complaint is confirmed to be supplier related.A lot history review (lhr) review is not possible, as no manufacturing lot number has been provided by the complainant.
|